Literature DB >> 15657204

Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.

M-A von Mach1, A Eich, L S Weilemann, T Münzel.   

Abstract

Clopidogrel, in combination with aspirin, is commonly used for the prevention of thrombosis in patients who have received coronary artery stents. As a rare but critical complication, clopidogrel associated thrombotic thrombocytopenic purpura (TTP) has previously been described. A 78 year old man presented with unstable angina and filiform subtotal stenosis of the left anterior descending artery. He was treated with balloon angioplasty and stent implantation. After four days the patient again had angina caused by stent thrombosis, which was treated with balloon angioplasty. During hospital stay the typical course of clopidogrel associated TTP was observed with thrombocytopenia and petechial purpura occurring 14 days after drug initiation and prompt response to therapeutic plasma exchanges. These findings strongly suggest that clopidogrel may have increased platelet activation and aggregation in this immunologically susceptible patient, ultimately leading to a stent thrombosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657204      PMCID: PMC1768676          DOI: 10.1136/hrt.2004.049122

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

1.  Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.

Authors:  I Müller; M Seyfarth; S Rüdiger; B Wolf; G Pogatsa-Murray; A Schömig; M Gawaz
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

2.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).

Authors:  M E Bertrand; H J Rupprecht; P Urban; A H Gershlick
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

3.  G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation.

Authors:  H Ceelie; C C Spaargaren-van Riel; R M Bertina; H L Vos
Journal:  J Thromb Haemost       Date:  2004-01       Impact factor: 5.824

Review 4.  The antiplatelet effects of ticlopidine and clopidogrel.

Authors:  P J Sharis; C P Cannon; J Loscalzo
Journal:  Ann Intern Med       Date:  1998-09-01       Impact factor: 25.391

5.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

6.  Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; L Rice; R Sarode; T W Chow; J L Moake
Journal:  Ann Intern Med       Date:  2000-05-16       Impact factor: 25.391

7.  Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

Authors:  K Fujikawa; H Suzuki; B McMullen; D Chung
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

8.  Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

Authors:  S R Steinhubl; W A Tan; J M Foody; E J Topol
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

9.  Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.

Authors:  Anaadriana Zakarija; Nicholas Bandarenko; Dilip K Pandey; Amy Auerbach; Dennis W Raisch; Benjamin Kim; Hau C Kwaan; June M McKoy; Brian P Schmitt; Charles J Davidson; Paul R Yarnold; Philip B Gorelick; Charles L Bennett
Journal:  Stroke       Date:  2004-01-05       Impact factor: 7.914

  9 in total
  3 in total

Review 1.  Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  Profound thrombocytopenia induced by clopidogrel with a prior history of long-term safe administration.

Authors:  Yuan-Lin Guo; Jian-Jun Li; Jin-Qing Yuan; Xue-Wen Qin; Xin Zheng; Chao-Wei Mu; Yi-Hong Hua
Journal:  World J Cardiol       Date:  2010-06-26

3.  Patient with recent coronary artery stent requiring major non cardiac surgery.

Authors:  Usha Kiran; Neeti Makhija
Journal:  Indian J Anaesth       Date:  2009-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.